Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved dosing in Cohort 8 of ENDEAVOR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback